Drug intelligence / Profile preview

waglerin-1

Development stage
Unknown
Modality
Peptides
Administration
Intraperitoneal, Subcutaneous
01

Overview

Waglerin-1 is a 22-amino acid peptide toxin originally isolated from the venom of the Southeast Asian Wagler's pit viper (*Trimeresurus wagleri*). It acts as a potent and selective competitive antagonist of the adult-type muscle nicotinic acetylcholine receptor (nAChR), specifically targeting the epsilon (ε) subunit interface. Due to its high affinity for the adult (α1₂β1δε) versus fetal (α1₂β1δγ) nAChR subtypes, it is widely utilized as a pharmacological tool to differentiate between these receptor forms. Additionally, Waglerin-1 has been shown to modulate GABA(A) receptors in a neuron-specific manner, exhibiting both potentiating and suppressing effects. While not an approved therapeutic, its muscle-relaxing properties have led to the development of synthetic derivatives for use in topical cosmetic applications to reduce the appearance of fine lines and wrinkles.

Other names
Waglerin-IWaglerin 1Waglerin1Waglerin-1
02

Targets

GABRR (GABA-A receptor subunit rho)Muscle-type nicotinic acetylcholine receptor

Beyond the preview

Go deeper on waglerin-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on waglerin-1.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call